An antibody that targets cell‐surface glucose‐regulated protein‐78 inhibits expression of inflammatory cytokines and plasminogen activator inhibitors by macrophages
- 22 March 2023
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 124 (5), 743-752
- https://doi.org/10.1002/jcb.30401
Abstract
Glucose-regulated protein-78 (Grp78) is an endoplasmic reticulum chaperone, which is secreted by cells and associates with cell surfaces, where it functions as a receptor for activated a(2)-macroglobulin (a(2)M) and tissue-type plasminogen activator (tPA). In macrophages, a(2)M and tPA also bind to the transmembrane receptor, LDL receptor-related protein-1 (LRP1), activating a cell-signaling receptor assembly that includes the NMDA receptor (NMDA-R) to suppress innate immunity. Herein, we demonstrate that an antibody targeting Grp78 (N88) inhibits NF?B activation and expression of proinflammatory cytokines in bone marrow-derived macrophages (BMDMs) treated with the toll-like receptor-4 (TLR4) ligand, lipopolysaccharide, or with agonists that activate TLR2, TLR7, or TLR9. Pharmacologic inhibition of the NMDA-R or deletion of the gene encoding LRP1 (Lrp1) in BMDMs neutralizes the activity of N88. The fibrinolysis protease inhibitor, plasminogen activator inhibitor-1 (PAI1), has been implicated in diverse diseases including metabolic syndrome, cardiovascular disease, and type 2 diabetes. Deletion of Lrp1 independently increased expression of PAI1 and PAI2 in BMDMs, as did treatment of wild-type BMDMs with TLR agonists. tPA, a(2)M, and N88 inhibited expression of PAI1 and PAI2 in BMDMs treated with TLR-activating agents. Inhibiting Src family kinases blocked the ability of both N88 and tPA to function as anti-inflammatory agents, suggesting that the cell-signaling pathway activated by tPA and N88, downstream of LRP1 and the NMDA-R, may be equivalent. We conclude that targeting cell-surface Grp78 may be effective in suppressing innate immunity by a mechanism that requires LRP1 and the NMDA-R.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01 HL136395)
This publication has 47 references indexed in Scilit:
- Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cellsJournal of Proteomics, 2012
- A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in miceMelanoma Research, 2012
- CD91-dependent programming of T-helper cell responses following heat shock protein immunizationNature Communications, 2011
- Inflammatory mediators promote production of shed LRP1/CD91, which regulates cell signaling and cytokine expression by macrophagesJournal of Leukocyte Biology, 2010
- Ligand Binding to LRP1 Transactivates Trk Receptors by a Src Family Kinase–Dependent PathwayScience Signaling, 2009
- γ-Secretase Limits the Inflammatory Response Through the Processing of LRP1Science Signaling, 2008
- Tissue‐type plasminogen activator requires a co‐receptor to enhance NMDA receptor functionJournal of Neurochemistry, 2008
- Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activitiesEuropean Journal of Immunology, 2003
- Platelet-derived Growth Factor Mediates Tyrosine Phosphorylation of the Cytoplasmic Domain of the Low Density Lipoprotein Receptor-related Protein in CaveolaeOnline Journal of Public Health Informatics, 2002
- Physical properties of human α2-macroglobulin following reaction with methylamine and trypsinBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1982